Literature DB >> 3207560

Effect of indomethacin on the pharmacokinetics and pharmacodynamics of felodipine.

B G Hardy1, W R Bartle, M Myers, D G Bailey, B Edgar.   

Abstract

1. We studied the effects of pre-treatment with oral indomethacin (25 mg four times daily for 3 days) on the pharmacokinetics, haemodynamics and diuretic properties of oral felodipine (10 mg single dose) in 12 healthy male volunteers using a placebo controlled double-blind four-way crossover protocol. 2. Felodipine with or without indomethacin pretreatment reduced standing diastolic blood pressure (P less than 0.001) at 0.5 to 3.0 h after dosing compared with placebo or indomethacin alone. Systolic blood pressures during indomethacin treatment alone were consistently higher than the other three treatment groups (P less than 0.01), presumably due to sodium and fluid retention. 3. Felodipine and felodipine plus indomethacin produced significantly greater excretion of urine and urinary sodium, but not of urinary potassium or creatinine when compared with placebo (P less than 0.01) over an 8 h period. 4. The pharmacokinetic parameters of felodipine (Cmax, tmax, t1/2 and AUC), the concentration-response curves for blood pressure lowering effects, the reflex tachycardia, diuretic properties and side-effects profile of felodipine were not significantly altered by indomethacin pretreatment in normal volunteers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3207560      PMCID: PMC1386632          DOI: 10.1111/j.1365-2125.1988.tb05295.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.

Authors:  J D Unadkat; F Bartha; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

2.  The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension.

Authors:  P L Katzman; U L Hulthén; B Hökfelt
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

Review 3.  Prostaglandins and regulation of blood pressure: clinical implications.

Authors:  J M Sullivan
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

4.  Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris.

Authors:  J V Sheridan; P Thomas; P A Routledge; D J Sheridan
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

5.  Felodipine kinetics in healthy men.

Authors:  B Edgar; C G Regårdh; G Johnsson; L Johansson; P Lundborg; I Löfberg; O Rönn
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

6.  Felodipine, blood pressure, and cardiovascular reflexes in hypertensive humans.

Authors:  S A Smith; P J Mace; W A Littler
Journal:  Hypertension       Date:  1986-12       Impact factor: 10.190

7.  Felodipine compared to nifedipine as "third-line drug" in resistant hypertension.

Authors:  D Maclean; E T Mitchell; A S Readman
Journal:  Angiology       Date:  1986-11       Impact factor: 3.619

Review 8.  Flushing reactions: consequences and mechanisms.

Authors:  J K Wilkin
Journal:  Ann Intern Med       Date:  1981-10       Impact factor: 25.391

9.  Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol.

Authors:  O Rönn; B Bengtsson; B Edgar; S Raner
Journal:  Drugs       Date:  1985       Impact factor: 9.546

10.  Effects of felodipine on renal function in animals.

Authors:  G F DiBona
Journal:  Drugs       Date:  1985       Impact factor: 9.546

View more
  7 in total

Review 1.  NSAIDs and blood pressure. Clinical importance for older patients.

Authors:  A G Johnson
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 2.  NSAIDs and increased blood pressure. What is the clinical significance?

Authors:  A G Johnson
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

Review 3.  Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective.

Authors:  P W de Leeuw
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

Review 4.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 5.  Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  J R Brouwers; P A de Smet
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

6.  Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study.

Authors:  A G Johnson; L A Simons; J Simons; Y Friedlander; J McCallum
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

7.  A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.

Authors:  Laura Maria Fuhr; Fatima Zahra Marok; Maximilian Mees; Felix Mahfoud; Dominik Selzer; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.